Playback speed
10 seconds
This video is featured in the 2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "QoL Data With Neoadjuvant Ipi & Nivo in Resectable Stage III Melanoma - 36-Week Data From the NADINA Trial"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Judith Lijnsvelt
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Judith Lijnsvelt
57 views
June 14, 2024
Chapters
Neoadjuvant Therapy & NADINA Trial Overview
00:00
Adverse Events & Patient Experience
02:41
Quality of Life Data & Conclusions
04:56
Comments 0
Login to view comments.
Click here to Login
2024 ASCO® Annual Meeting Insights Hub: Skin Videos
Recommended
AUTOPLAY